Group B Streptococcus

Group B Streptococcus (GBS) infection is the infection caused by the bacterium Streptococcus agalactiae. Group B streptococcal infection can cause serious illness and sometimes death, especially in newborns, the elderly, and people with compromised immune systems. In general, GBS is a harmless commensal bacterium, being part of the human microbiota colonizing the gastrointestinal and genitourinary tracts of up to 30% of healthy human adults (asymptomatic carriers). Vaginal colonization rates range from 4 to 36%, with most studies reporting over 20%.

GBS is the main cause of bacterial infections in newborns, such as septicemia, pneumonia, and meningitis, which can lead to death or long-term after-effects. Infections in newborns are separated into two clinical types: early-onset disease (EOGBS) and late-onset disease (LOGBS). EOGBS manifests from 0 to 7 living days in the newborn, with most of the cases being apparent within 24 hours. LOGBS starts between 7 and 90 days after birth. EOGBS is acquired through exposure of the fetus or baby to GBS from the vagina either in utero or during birth.

available-testAvailable Test

Group B Streptococcus Panel.

testTest Information

Organism List:

Staphylococcus agalactiae.

Clinical Utility:

Retrogen offers early & accurate detection, rapid turnaround times, and only requires a single, non-invasive sample collection. Your referring physician will be provided with a detailed, comprehensive report that leads to actionable decisions and forward treatment options.


Retrogen carries out real-time molecular PCR on DNA extracted from vaginal swabs to screen for microorganisms. This quantitative approach uses TaqMan chemistry from Life Technologies to detect pathogen-specific gene sequences.

order Ordering

Test ID:

Turnaround Time:

Preferred Specimen:


24-48 hours.

Vaginal swab.

billing Billing

CPT Codes:

Billing Information:

87081, 87150. MIC performed add charge 87186 or 87184.

View Billing Information

refer References
  1. Amsel R, Totten PA, Spiegel CA, et al. Nonspecific vaginitis: Diagnostic criteria and microbial and epidemiologic associations. Am J Med 74(1):14-22, 1983.
  2. Verstraelen H, Verhelsy R. Bacterial vaginosis: An update on diagnosis and treatment. Expert Rev Anti Infect Ther 7(9):1109-1124, 2009.
  3. Spiegel C, Amsel R, Holmes K. Diagnosis of bacterial vaginosis by direct gram stain of vaginal fluid. J. Clin. Microbiol. July 1983 vol. 18 no. 1, 170-177.
  4. Workowski, KA; Berman, S; Centers for Disease Control and Prevention, (CDC) (17 December 2010). "Sexually transmitted diseases treatment guidelines, 2010." MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports / Centers for Disease Control. 59 (RR-12): 1-110.
  5. Warner L, Klausner JD, Rietmeijer CA, et al. Effect of a brief video intervention on incident infec- tion among patients attending sexually transmitted disease clinics. PLoS Med 2008;5:919-27..
  6. Clement, Meredith E.; Okeke, N. Lance; Hicks, Charles B. (2014). "Treatment of Syphilis". JAMA. 312 (18): 1905.


CALL 1-800-RETROGEN OR (858) 455-8411